Axial spondyloarthritis

At the 12-month mark, 52% of patients in the axSpA cohort and 76% of those in the IBD cohort achieved clinical remission.

There were no significant safety issues in the group of patients treated with secukinumab for more than 3 years.

Data from the CONSUL trial provide insight into the effects of TNF inhibitor monotherapy compared against combination therapy with NSAIDs for blunting radiographic spinal progression in adults with radiographic axial spondyloarthritis.

An analysis of more than 17,000 Veterans suggests early initiation of TNF inhibitor therapy in patients with ankylosing spondylitis was associated with an increased risk of incident cardiovascular disease and major adverse cardiovascular events.

Désirée van der Heijde, MD, PhD, explains the results of a recent trial evaluating the safety and efficacy of bimekizumab in patients with active ankylosing spondylitis.

Upadacitinib met the primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis and treatment-refractory active ankylosing spondylitis with inadequate response to biologic disease-modifying antirheumatic drugs.

Of 185 outpatients that completed the questionnaire, 146 patients (78.9%) were considered to have poor adherence to exercise therapy.

The European Alliance of Associations for Rheumatology (EULAR) recommends screening and early management of cardiovascular disease in patients with radiographic axial spondyloarthritis.

On April 29, AbbVie announced the US FDA had granted approval to upadacitinib 15 mg (RINVOQ) for treatment of active ankylosing spondylitis among adult patients who had inadequate response or intolerance to at least 1 TNF inhibitor.

“Understanding the impact of axSpA on pregnancy outcomes is a vital component of improving management of women with axSpA at every stage of their lives,” investigators stated.

Jessica Walsh, MD, explains the importance of understanding treatment satisfaction and decision-making in patients with axial spondyloarthritis based on patient-reported outcomes.

“Managing pain is an important treatment goal in patients with ankylosing spondylitis, however, pain is often underestimated by clinical disease activity scoring tools, and 20% to 30% of patients report pain despite treatment with TNFis,” investigators stated.

Chronic back pain, a common symptom of axial spondyloarthritis that increases disease burden and reduces quality of life, may be improved by subcutaneous injection of secukinumab 150 mg or 300 mg.

Upadacitinib achieved positive results from both Phase 3 SELECT-AXIS clinical trials, which focused on patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.

The 2 studies focused on upadacitinib treatment for one group of patients with ankylosing spondylitis and another group of patients with non-radiographic axial spondyloarthritis.

Limited information is available on the overall disease burden of axial spondyloarthritis (axSpA) in women, as they are generally underrepresented in clinical studies.

“Understanding the role of ixekizumab will allow physicians to translate a higher Assessment of Spondyloarthritis International Society (ASAS) achievement to the improvements in the signs and symptoms reported by their patients,” investigators stated.

High levels of sedentary activity and low levels of physical activity found in patients with axSpA

"Physical activity and exercise have been shown to improve general well-being and reduce cardiovascular disease risk in the general population," investigators stated. "Despite these recommendations, studies show that levels of PA are reduced among patients with axial spondyloarthritis.”

The Epionics SPINE is an innovative tool to assess the spinal mobility of patients with axial spondyloarthritis.

Investigators from Turkey show how static foot posture in patients with rheumatic diseases can lead to impairment of physical function due enthesitis.

Atul Deodhar, MD, MRCP, discusses his recent study investigating the efficacy and safety of upadacitinib in active ankylosing Spondylitis, including study design, results, and its clinical significance.

Investigators discovered that women with axial spondyloarthritis (axSpA) have an overall higher disease burden and more peripheral manifestations when compared with men. They further theorized that awareness of these differences and the way the condition presents differently in both sexes may be used to more easily identify axSpA and improve disease management.

Artificial intelligence (AI) detected axial spondyloarthritis (axSpA) in radiographic scans of sacroiliac joints as accurately as human experts, shows a new study.